On August 5, 2026, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B financing led by General Atlantic, a leading global investor, with participation from RA Capital and Vivo Capital and existing investors Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma (a platform controlled by KKR), Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners. Wilson Sonsini Goodrich & Rosati is patent counsel to Expedition and advises the company on all patent matters, including those related to this transaction.

The financing will support advancement of the company’s lead DPP1 inhibitor EXPD-101 through Phase 2 clinical development, expand its pipeline of next-generation therapies for inflammatory diseases, and further enhance its research discovery.

The Wilson Sonsini team that advised Expedition on patent matters includes Michael Hostetler, Val Zunic, Norm Hovijitra, and Tyler Baguley.

For more information, please see Expedition’s news release.